Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer

Maurizio Vaglini, Federico Cascinelli, Arturo Chiti, Marcello Deraco, Maria Grazia Inglese, Giacomo Rebuffoni, Maurilia Rizzi, Barbara Sala, Nicola Santoro, Mario Santinami

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Between May 1990 and December 1995, 16 patients with primary or recurrent unresectable rectal cancer were treated by isolated pelvic perfusion. All patients had been previously treated and were considered unsuitable for surgery or further systemic chemotherapy or radiotherapy. The treatment was based on a perfusion lasting 90 min at 40.5°C with 5-fluorouracil, mitomycin-C and mitoxantrone. Whenever technically feasible (10 cases), continuous intraarterial chemotherapy (through a Medtronic device with a catheter in the inferior mesenteric artery) was administered postoperatively. Two complete responses and 2 partial responses were observed; 8 other patients showed stable disease. One patient did not show any response. Finally, 3 patients for various reasons were not assessable. All patients experienced immediate relief of pain. No major side effects directly related to isolated pelvic perfusion were recorded; a transitory bone marrow depletion was observed in all cases. In conclusion, isolated pelvic perfusion is useful in inoperable disease of the pelvis by reliably relieving pain and thereby improving the patients quality of life.

Original languageEnglish
Pages (from-to)459-462
Number of pages4
JournalTumori
Volume82
Issue number5
Publication statusPublished - Sep 1996

Fingerprint

Rectal Neoplasms
Perfusion
Therapeutics
Inferior Mesenteric Artery
Drug Therapy
Pain
Mitoxantrone
Mitomycin
Pelvis
Fluorouracil
Radiotherapy
Catheters
Bone Marrow
Quality of Life
Equipment and Supplies

Keywords

  • hyperthermia
  • pelvic recurrences
  • perfusion
  • rectal cancer
  • regional therapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer. / Vaglini, Maurizio; Cascinelli, Federico; Chiti, Arturo; Deraco, Marcello; Inglese, Maria Grazia; Rebuffoni, Giacomo; Rizzi, Maurilia; Sala, Barbara; Santoro, Nicola; Santinami, Mario.

In: Tumori, Vol. 82, No. 5, 09.1996, p. 459-462.

Research output: Contribution to journalArticle

Vaglini, M, Cascinelli, F, Chiti, A, Deraco, M, Inglese, MG, Rebuffoni, G, Rizzi, M, Sala, B, Santoro, N & Santinami, M 1996, 'Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer', Tumori, vol. 82, no. 5, pp. 459-462.
Vaglini M, Cascinelli F, Chiti A, Deraco M, Inglese MG, Rebuffoni G et al. Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer. Tumori. 1996 Sep;82(5):459-462.
Vaglini, Maurizio ; Cascinelli, Federico ; Chiti, Arturo ; Deraco, Marcello ; Inglese, Maria Grazia ; Rebuffoni, Giacomo ; Rizzi, Maurilia ; Sala, Barbara ; Santoro, Nicola ; Santinami, Mario. / Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer. In: Tumori. 1996 ; Vol. 82, No. 5. pp. 459-462.
@article{b4645230b55e4b8e918be827d001dd3d,
title = "Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer",
abstract = "Between May 1990 and December 1995, 16 patients with primary or recurrent unresectable rectal cancer were treated by isolated pelvic perfusion. All patients had been previously treated and were considered unsuitable for surgery or further systemic chemotherapy or radiotherapy. The treatment was based on a perfusion lasting 90 min at 40.5°C with 5-fluorouracil, mitomycin-C and mitoxantrone. Whenever technically feasible (10 cases), continuous intraarterial chemotherapy (through a Medtronic device with a catheter in the inferior mesenteric artery) was administered postoperatively. Two complete responses and 2 partial responses were observed; 8 other patients showed stable disease. One patient did not show any response. Finally, 3 patients for various reasons were not assessable. All patients experienced immediate relief of pain. No major side effects directly related to isolated pelvic perfusion were recorded; a transitory bone marrow depletion was observed in all cases. In conclusion, isolated pelvic perfusion is useful in inoperable disease of the pelvis by reliably relieving pain and thereby improving the patients quality of life.",
keywords = "hyperthermia, pelvic recurrences, perfusion, rectal cancer, regional therapy",
author = "Maurizio Vaglini and Federico Cascinelli and Arturo Chiti and Marcello Deraco and Inglese, {Maria Grazia} and Giacomo Rebuffoni and Maurilia Rizzi and Barbara Sala and Nicola Santoro and Mario Santinami",
year = "1996",
month = "9",
language = "English",
volume = "82",
pages = "459--462",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer

AU - Vaglini, Maurizio

AU - Cascinelli, Federico

AU - Chiti, Arturo

AU - Deraco, Marcello

AU - Inglese, Maria Grazia

AU - Rebuffoni, Giacomo

AU - Rizzi, Maurilia

AU - Sala, Barbara

AU - Santoro, Nicola

AU - Santinami, Mario

PY - 1996/9

Y1 - 1996/9

N2 - Between May 1990 and December 1995, 16 patients with primary or recurrent unresectable rectal cancer were treated by isolated pelvic perfusion. All patients had been previously treated and were considered unsuitable for surgery or further systemic chemotherapy or radiotherapy. The treatment was based on a perfusion lasting 90 min at 40.5°C with 5-fluorouracil, mitomycin-C and mitoxantrone. Whenever technically feasible (10 cases), continuous intraarterial chemotherapy (through a Medtronic device with a catheter in the inferior mesenteric artery) was administered postoperatively. Two complete responses and 2 partial responses were observed; 8 other patients showed stable disease. One patient did not show any response. Finally, 3 patients for various reasons were not assessable. All patients experienced immediate relief of pain. No major side effects directly related to isolated pelvic perfusion were recorded; a transitory bone marrow depletion was observed in all cases. In conclusion, isolated pelvic perfusion is useful in inoperable disease of the pelvis by reliably relieving pain and thereby improving the patients quality of life.

AB - Between May 1990 and December 1995, 16 patients with primary or recurrent unresectable rectal cancer were treated by isolated pelvic perfusion. All patients had been previously treated and were considered unsuitable for surgery or further systemic chemotherapy or radiotherapy. The treatment was based on a perfusion lasting 90 min at 40.5°C with 5-fluorouracil, mitomycin-C and mitoxantrone. Whenever technically feasible (10 cases), continuous intraarterial chemotherapy (through a Medtronic device with a catheter in the inferior mesenteric artery) was administered postoperatively. Two complete responses and 2 partial responses were observed; 8 other patients showed stable disease. One patient did not show any response. Finally, 3 patients for various reasons were not assessable. All patients experienced immediate relief of pain. No major side effects directly related to isolated pelvic perfusion were recorded; a transitory bone marrow depletion was observed in all cases. In conclusion, isolated pelvic perfusion is useful in inoperable disease of the pelvis by reliably relieving pain and thereby improving the patients quality of life.

KW - hyperthermia

KW - pelvic recurrences

KW - perfusion

KW - rectal cancer

KW - regional therapy

UR - http://www.scopus.com/inward/record.url?scp=12644267271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12644267271&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 459

EP - 462

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -